Former Exec Director-Strategic Affairs & Economic Analysis Ann-Marie Lynch is new VP-policy for the Pharmaceutical Research & Manufacturers of America, reporting to Exec VP Judith Bello. Lynch succeeds Steve Cole, who is leaving the association. Lynch joined PhRMA in January from the staff of Rep. Thomas' (R-Calif.) Ways & Means/Health Subcommittee (1"The Pink Sheet" Jan. 10, p. 16). The PhRMA policy team is adding another House Republican staffer: former Commerce/Oversight Subcommittee majority counsel Lori Wall starts as director of policy Sept. 11 (2"The Pink Sheet" Sept. 4, In Brief). Cole joined PhRMA in 1997 from the Federation of American Health Systems
You may also be interested in...
House Commerce Committee majority counsel Lori Wall will join the Pharmaceutical Research & Manufacturers of America as a policy director. Wall worked with the Oversight Subcommittee on its investigation of ordering pharmaceuticals over the Internet
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials